JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 20, 2003; DOI: 10.1124/jpet.103.058701


0022-3565/04/3081-206-213$20.00
JPET 308:206-213, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.058701v1
308/1/206    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venkova, K.
Right arrow Articles by Meerveld, B. G.-V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venkova, K.
Right arrow Articles by Meerveld, B. G.-V.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Oral Treatment with Recombinant Human Interleukin-11 Improves Mucosal Transport in the Colon of Human Leukocyte Antigen-B27 Transgenic Rats

Kalina Venkova, James C. Keith, Jr., and Beverley Greenwood-Van Meerveld

Oklahoma Foundation for Digestive Research Basic Science Laboratories, Veterans Affairs Medical Center, Oklahoma City, Oklahoma (K.V., B.G.V.M.); and Discovery Research, Wyeth Research, Cambridge, Massachusetts (J.C.K.)

Recombinant human interleukin (IL)-11 is a pleiotropic cytokine with anti-inflammatory activity. The objective of the study was to investigate whether oral treatment with rhIL-11 improves colonic epithelial dysfunction in the human leukocyte antigen (HLA)-B27 transgenic rat model of spontaneous chronic inflammation. Experiments were performed using adult male HLAB27 rats, whereas healthy nontransgenic F344 rats served as controls. Enteric-coated rhIL-11 multi-particles (equivalent to 500 µg/kg rhIL11) or placebo (formulation lacking rhIL-11) were administrated orally on alternate days for 2 weeks to HLA-B27 or F344 rats. Stool character was observed daily during the treatment period. Animals were euthanized at the end of treatment and colonic inflammation was evaluated be measuring tissue myeloperoxidase (MPO) activity. Epithelial transport in isolated colonic mucosal sheets was studied in modified Ussing chambers. Oral treatment of HLA-B27 rats with rhIL-11 reduced MPO activity in the colon and suppressed the clinical signs of diarrhea. The electrophysiological characteristics of mucosal transport were improved in the HLA-B27 rats treated with rhIL-11 compared with placebo. After rhIL-11 treatment the basal transepithelial resistance and the estimated paracellular resistance were significantly increased, neurally mediated secretory responses to electrical field stimulation were improved, and cholinoceptor sensitivity was normalized. Treatment with rhIL-11 had no significant effect on basal short circuit current and the maximal secretory response to carbachol or substance P. Our data demonstrate that oral rhIL-11 therapy is associated with suppression of mucosal inflammation and a concomitant improvement of epithelial resistance and neurally mediated secretion in a model of chronic HLA-B27 colitis.


Received August 15, 2003; accepted October 9, 2003.

Address correspondence to: Dr. Beverley Greenwood-Van Meerveld, V.A. Medical Center, Research Administration Room 151, 921 NE 13th St., Oklahoma City, OK 73104. E-mail: beverley-greenwood{at}ouhsc.edu




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Boerma, J. Wang, A. F. Burnett, A. D. Santin, J. J. Roman, and M. Hauer-Jensen
Local Administration of Interleukin-11 Ameliorates Intestinal Radiation Injury in Rats
Cancer Res., October 1, 2007; 67(19): 9501 - 9506.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Q. Chen, L. Rabach, P. Noble, T. Zheng, C. G. Lee, R. J. Homer, and J. A. Elias
IL-11 Receptor {alpha} in the Pathogenesis of IL-13-Induced Inflammation and Remodeling
J. Immunol., February 15, 2005; 174(4): 2305 - 2313.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.